Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note released on Monday.

Abeona Therapeutics Stock Down 5.0 %

Shares of NASDAQ ABEO opened at $7.53 on Monday. The business has a fifty day simple moving average of $7.44 and a two-hundred day simple moving average of $5.59. The firm has a market cap of $205.95 million, a PE ratio of -2.92 and a beta of 1.49. Abeona Therapeutics has a twelve month low of $2.83 and a twelve month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). On average, research analysts expect that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ABEO. Vanguard Group Inc. boosted its stake in shares of Abeona Therapeutics by 46.2% in the fourth quarter. Vanguard Group Inc. now owns 1,101,131 shares of the biopharmaceutical company’s stock worth $5,517,000 after buying an additional 348,196 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Abeona Therapeutics by 21.4% in the fourth quarter. Northern Trust Corp now owns 131,923 shares of the biopharmaceutical company’s stock worth $661,000 after buying an additional 23,276 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth about $199,000. Citigroup Inc. boosted its stake in shares of Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock worth $1,894,000 after buying an additional 250,000 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Abeona Therapeutics in the third quarter worth about $59,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.